Children With Rare Non-Hepatoblastoma Liver Tumors Show Encouraging Survival Outcomes, Suggests Study
A recent retrospective study published in the Indian Journal of Gastroenterology reveals surprisingly favorable survival outcomes for children treated for rare non-hepatoblastoma liver tumors. These encouraging results were observed despite an unexpectedly high presence of aggressive rhabdoid tumors and massively elevated tumor markers in the patients.
While extensive previous surveillance databases establish hepatoblastoma as the predominant pediatric liver malignancy, a significant clinical knowledge gap persists regarding the epidemiology and management of rarer primary n-HB variants that typically arise without underlying cirrhosis. Addressing this disparity, Dr. Abha Mehta, alongside colleagues from the Tata Memorial Hospital, Homi Bhabha National Institute, aimed to comprehensively evaluate the demographic characteristics and clinical outcomes of these exceptionally rare neoplasms.
Therefore, the retrospective study analyzed 69 children over a decade to determine the epidemiological profile of rare non-hepatoblastoma liver tumors. Additionally, it evaluated the targeted treatment strategies and overall patient survival outcomes.
Key Clinical Findings of the Study Includes:
Prevalence Spectrum: Investigators noted that these rare variants constituted 15.7% of all pediatric primary liver tumors, with infantile hepatic hemangioma (IHH) dominating the zero-to-six-month age group at 66.7% and HCC prevailing in older pediatric patients at 45.4%.
Biomarker Elevations: Researchers highlighted an exceptionally high median AFP level of 131,249 ng/mL among HCC patients, despite a surprisingly low 18.7% incidence of underlying cirrhosis compared to established historical cohorts.
Clinical Presentation: Analysis revealed that unlike typical hepatoblastoma cases, where discomfort is typically absent, these malignant hepatic tumors primarily manifested with prominent abdominal pain in 63.4% of subjects and distension in 43.9%.
Treatment Modalities: Professionals observed that among the 73.9% of subjects who received targeted therapies, surgical resection was heavily utilized in 85.2% of the cases alongside multiagent systemic chemotherapy regimens in 81.5%.
Survival Rates: Data demonstrated encouraging long-term outcomes in the treated cohort, with relatively low relapse or mortality rates documented for critical malignancies like HCC at 22.2% and undifferentiated embryonal sarcoma of the liver (UESL) at 33.3%.
The results suggest that despite the aggressive histological nature, unexpectedly high AFP levels, and advanced clinical presentation of certain pediatric n-HB hepatic malignancies, localized surgical resection combined with systemic interventions yields surprisingly favorable overall prognostic outcomes.
Because significant tumor marker elevations are frequently observed across diverse hepatic neoplasms, the study concludes clinicians should carefully consider an immediate tissue biopsy to secure an accurate definitive diagnosis whenever patient age or specific radiological presentations substantially diverge from classic hepatoblastoma patterns.
While constrained by its retrospective design, potential institutional referral bias, small sample sizes across isolated histological subtypes, and a complete absence of germline or molecular data, this institutional review gently underscores the necessity for comprehensive, prospective national registries and collaborative multicenter investigations to further inform targeted therapeutic strategies.
Reference
Mehta, A., Parambil, B.C., Baheti, A., et al. Primary non-hepatoblastoma liver tumors in children—Defining the profile of a very rare subset of childhood tumors. Indian Journal of Gastroenterology 45(4): 697–705 (2026).
